Xin Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xin Hao has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Fei Gao
3 shared publicationsZe Yu
3 shared publicationsJinyuan Zhang
Beijing Medicinovo Technology Co., Ltd. Beijing China
2 shared publications- Chunhua Zhou
Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publication Chunming Lyu
Shanghai University of Traditional Chinese Medicine
1 shared publicationFang Kou
1 shared publication
Latest Publications
- Open Access
- 1 June 2023
- Published by KEAI Publishing in Intelligent Pharmacy
- Vol. 1 (1) , 11-16
Application and development of real-world study on Chinese patent medicine
- 1 June 2023
- Published by KEAI Publishing in Intelligent Pharmacy
- Vol. 1 (1) , 11-16
Open AccessApplication and development of real-world study on Chinese patent medicine
- 7 May 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (9) , 2714-2725
A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real‐world data
Aims: This study aimed to establish a prediction model of quetiapine concentration in patients with schizophrenia and depression, based on real‐world data via machine learning techniques to assist clinical regimen decisions.Methods: A total of 650 cases of quetiapine therapeutic drug monitoring (TDM) data from 483 patients at the First Hospital of Hebei Medical University from 1 November 2019 to 31 August 2022 were included in the study. Univariate analysis and sequential forward selection (SFS) were implemented to screen the important variables influencing quetiapine TDM. After 10‐fold cross validation, the algorithm with the optimal model performance was selected for predicting quetiapine TDM among nine models. SHapley Additive exPlanation was applied for model interpretation.Results: Four variables (daily dose of quetiapine, type of mental illness, sex and CYP2D6 competitive substrates) were selected through univariate analysis (P < .05) and SFS to establish the models. The CatBoost algorithm with the best predictive ability (mean [SD] R2 = 0.63 ± 0.02, RMSE = 137.39 ± 10.56, MAE = 103.24 ± 7.23) was chosen for predicting quetiapine TDM among nine models. The mean (SD) accuracy of the predicted TDM within ±30% of the actual TDM was 49.46 ± 3.00%, and that of the recommended therapeutic range (200–750 ng mL−1) was 73.54 ± 8.3%. Compared with the PBPK model in a previous study, the CatBoost model shows slightly higher accuracy within ±100% of the actual value.Conclusions: This work is the first real‐world study to predict the blood concentration of quetiapine in patients with schizophrenia and depression using artificial intelligent techniques, which is of significance and value for clinical medication guidance.
- 7 May 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (9) , 2714-2725
A machine learning model for predicting blood concentration of quetiapine in patients with schizophrenia and depression based on real‐world data
Aims: This study aimed to establish a prediction model of quetiapine concentration in patients with schizophrenia and depression, based on real‐world data via machine learning techniques to assist clinical regimen decisions.Methods: A total of 650 cases of quetiapine therapeutic drug monitoring (TDM) data from 483 patients at the First Hospital of Hebei Medical University from 1 November 2019 to 31 August 2022 were included in the study. Univariate analysis and sequential forward selection (SFS) were implemented to screen the important variables influencing quetiapine TDM. After 10‐fold cross validation, the algorithm with the optimal model performance was selected for predicting quetiapine TDM among nine models. SHapley Additive exPlanation was applied for model interpretation.Results: Four variables (daily dose of quetiapine, type of mental illness, sex and CYP2D6 competitive substrates) were selected through univariate analysis (P < .05) and SFS to establish the models. The CatBoost algorithm with the best predictive ability (mean [SD] R2 = 0.63 ± 0.02, RMSE = 137.39 ± 10.56, MAE = 103.24 ± 7.23) was chosen for predicting quetiapine TDM among nine models. The mean (SD) accuracy of the predicted TDM within ±30% of the actual TDM was 49.46 ± 3.00%, and that of the recommended therapeutic range (200–750 ng mL−1) was 73.54 ± 8.3%. Compared with the PBPK model in a previous study, the CatBoost model shows slightly higher accuracy within ±100% of the actual value.Conclusions: This work is the first real‐world study to predict the blood concentration of quetiapine in patients with schizophrenia and depression using artificial intelligent techniques, which is of significance and value for clinical medication guidance.
- Open Access
- 5 May 2023
- Published by Wiley
Individualized medication model of vancomycin in patients with renal insufficiency using machine learning techniques
Objectives: Inappropriate dose of vancomycin can cause nephrotoxicity, which should be avoided in clinical, particularly in patients with renal insufficiency. We aim to use machine learning techniques to explore important variables influencing vancomycin dose in patients with renal insufficiency and establish an individualized medication model to benefit these patients. Methods: Vancomycin administration cases in patients with renal insufficiency were collected at Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine from May 2018 to March 2022. Sequential Forward Selection was used for feature selection. Eight machine learning algorithms were compared the predictive performance, including XGBoost, LightGBM, CatBoost, GBDT, RF, SVC, KNN, and Logistic Regression. The one with the best predictive performance was chosen to calculate the importance score of modeling variables and establish the individualized medication model. Dose subgroups were divided into 500 mg, 1000 mg, 1500 mg and 2000 mg. Subgroup analysis based on the modeling variables were conducted. Results: This study included 237 eligible patients with 351 vancomycin cases. Six important variables were screened out, including gender, weight, AUC, uric acid, creatinine and total protein. CatBoost was chosen with the best prediction performance (accuracy=0.59) for modeling. The individualized medication model had precision over 53% and recall rate over 50% among all dose subgroups. The prediction of 1500 mg vancomycin had the best precision (65%), recall rate (71%) and F1-score (0.68). Conclusion: The individualized medication model of vancomycin for patients with renal insufficiency has good predictive performance, which can help clinicians make better decision of vancomycin use.
- 5 May 2023
- Published by Wiley
Open AccessIndividualized medication model of vancomycin in patients with renal insufficiency using machine learning techniques
Objectives: Inappropriate dose of vancomycin can cause nephrotoxicity, which should be avoided in clinical, particularly in patients with renal insufficiency. We aim to use machine learning techniques to explore important variables influencing vancomycin dose in patients with renal insufficiency and establish an individualized medication model to benefit these patients. Methods: Vancomycin administration cases in patients with renal insufficiency were collected at Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine from May 2018 to March 2022. Sequential Forward Selection was used for feature selection. Eight machine learning algorithms were compared the predictive performance, including XGBoost, LightGBM, CatBoost, GBDT, RF, SVC, KNN, and Logistic Regression. The one with the best predictive performance was chosen to calculate the importance score of modeling variables and establish the individualized medication model. Dose subgroups were divided into 500 mg, 1000 mg, 1500 mg and 2000 mg. Subgroup analysis based on the modeling variables were conducted. Results: This study included 237 eligible patients with 351 vancomycin cases. Six important variables were screened out, including gender, weight, AUC, uric acid, creatinine and total protein. CatBoost was chosen with the best prediction performance (accuracy=0.59) for modeling. The individualized medication model had precision over 53% and recall rate over 50% among all dose subgroups. The prediction of 1500 mg vancomycin had the best precision (65%), recall rate (71%) and F1-score (0.68). Conclusion: The individualized medication model of vancomycin for patients with renal insufficiency has good predictive performance, which can help clinicians make better decision of vancomycin use.